MENU
Aim higher

ResistAIDS

New class of HIV inhibitors to overcome resistance to current drugs and improvement of a mouse model

Highly active antiretroviral therapy is very effective at controlling HIV replication and associated mortality and morbidity. However the emergence and spread of viruses resistant to the drugs currently used is a growing public health threat. We want to develop a new class of anti-HIV drug that is fully active on all viruses resistant to current therapeutics, and will deliver a drug fully validated in phases I and IIa Proof of Concept clinical trials, and an improved mouse model of HIV infection
Acronym: 
ResistAIDS
Project ID: 
10 239
Ranking: 
47
Cut-off: 
4
Start date: 
01-04-2016
Project Duration: 
36months
Project costs: 
3 324 530.00€
Technological Area: 
Microbiology
Market Area: 
Drug delivery and other equipment (including kidney dialysis machines)